Clarytix Biopharma is a clinical stage biopharma company focused on developing cutting-edge therapeutic solutions for PTSD and neuropsychiatric care. The company is committed to pioneering therapeutics that address PTSD and neuropsychiatric conditions through innovative solutions, leveraging advanced biopharmaceutical research to create targeted therapeutics designed specifically for mental health disorders. Clarytix is developing a breakthrough oral drug for PTSD that delivers fast-acting, synergistic relief through a novel neuroplastic mechanism. Preclinical trials have shown highly promising results, supporting a strong scientific rationale, and the drug is positioned for FDA fast-track designation via the 505(b)(2) pathway. The company is advancing toward clinical trials in Israel.
